` 867 (China Medical System Holdings Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

C
867
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, China Medical System Holdings Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +79% compared to the Hang Seng (Hong Kong)'s +30% growth.

Stocks Performance
867 vs Hang Seng (Hong Kong)

Loading
867
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
867 vs Hang Seng (Hong Kong)

Loading
867
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
867 vs Hang Seng (Hong Kong)

Loading
867
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
China Medical System Holdings Ltd vs Peers

Hang Seng (Hong Kong)
867
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

China Medical System Holdings Ltd
Glance View

Market Cap
32.4B HKD
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a notable player in the Chinese pharmaceutical landscape, has woven a strategy that cleverly integrates proprietary drug development with a robust marketing apparatus. Established in 1995 and headquartered in Shenzhen, the company has developed a knack for identifying pharmaceuticals and medical devices with promising potential. Their business model hinges on acquiring exclusive rights to a carefully curated portfolio of international products, which they then introduce to the burgeoning Chinese market. By leveraging their deep understanding of market dynamics and regulatory environments, they effectively roll out these products, ensuring that they meet local demand and adhere to high compliance standards. The company's revenue engine is powered predominantly by its dynamic sales and marketing network which spans across mainland China. They employ a multifaceted distribution model, partnering with an extensive range of hospitals and healthcare providers to facilitate widespread adoption of their products. But what truly sets China Medical System Holdings apart is its focus on products that are already well advanced within their lifecycle, minimizing the usual risks associated with early-stage pharmaceutical development. This strategic approach not only ensures steady cash flows but also reduces overhead costs associated with R&D, allowing them to reinvest profits into acquiring new products and expanding their market footprint. As such, their business thrives on a cycle of discernment and targeted expansion, positioning them as a formidable entity in the healthcare sector.

Intrinsic Value
13.14 HKD
Overvaluation 1%
Intrinsic Value
Price
C
Back to Top